MX2021003737A - Moduladores de monoacilglicerol lipasa. - Google Patents
Moduladores de monoacilglicerol lipasa.Info
- Publication number
- MX2021003737A MX2021003737A MX2021003737A MX2021003737A MX2021003737A MX 2021003737 A MX2021003737 A MX 2021003737A MX 2021003737 A MX2021003737 A MX 2021003737A MX 2021003737 A MX2021003737 A MX 2021003737A MX 2021003737 A MX2021003737 A MX 2021003737A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disorders
- formula
- monoacylglycerol lipase
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Compuestos fusionados de la Fórmula (I) y Fórmula (II), composiciones farmacéuticas que los contienen, métodos para fabricarlos y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con dolor, trastornos psiquiátricos, trastornos neurológicos (que incluyen, pero no se limitan a, trastorno depresivo mayor, depresión resistente al tratamiento, depresión ansiosa, trastorno bipolar), cánceres y afecciones oculares. (ver Fórmula) (I) y (ver Fórmula) (II); en donde R1, R2, R2a, R3, R3a, R4, y R4a se definen en la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738600P | 2018-09-28 | 2018-09-28 | |
PCT/IB2019/058240 WO2020065613A1 (en) | 2018-09-28 | 2019-09-27 | Monoacylglycerol lipase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003737A true MX2021003737A (es) | 2021-05-14 |
Family
ID=68109428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003737A MX2021003737A (es) | 2018-09-28 | 2019-09-27 | Moduladores de monoacilglicerol lipasa. |
Country Status (23)
Country | Link |
---|---|
US (3) | US20200102303A1 (es) |
EP (1) | EP3856178A1 (es) |
JP (1) | JP2022502424A (es) |
KR (1) | KR20210069080A (es) |
CN (1) | CN113164459A (es) |
AU (1) | AU2019350624A1 (es) |
BR (1) | BR112021005896A2 (es) |
CA (1) | CA3111380A1 (es) |
CL (1) | CL2021000757A1 (es) |
CO (1) | CO2021003944A2 (es) |
CR (1) | CR20210153A (es) |
EA (1) | EA202190886A1 (es) |
EC (1) | ECSP21021381A (es) |
IL (1) | IL281812A (es) |
JO (1) | JOP20210058A1 (es) |
MA (1) | MA53721A (es) |
MX (1) | MX2021003737A (es) |
NI (1) | NI202100023A (es) |
PE (1) | PE20211773A1 (es) |
PH (1) | PH12021550659A1 (es) |
SG (1) | SG11202102281VA (es) |
TW (1) | TW202028198A (es) |
WO (1) | WO2020065613A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | P2x7調節劑 |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
KR20210069080A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
AU2020358948A1 (en) * | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
WO2022150962A1 (en) * | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
WO2023110958A1 (en) | 2021-12-16 | 2023-06-22 | F. Hoffmann-La Roche Ag | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
AU2003244632A1 (en) | 2002-07-25 | 2004-02-25 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
BR0312913A (pt) | 2002-07-25 | 2005-07-12 | Pharmacia Italia Spa | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
DE602005022320D1 (de) | 2004-08-23 | 2010-08-26 | Merck Sharp & Dohme | Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes |
EP1844003A4 (en) | 2005-01-27 | 2010-09-22 | Astrazeneca Ab | NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
US8349858B2 (en) | 2007-06-21 | 2013-01-08 | Merck Sharp & Dohme | Polycyclic guanine derivatives and use thereof |
UA99729C2 (en) | 2007-08-10 | 2012-09-25 | Х. Луннбек А/С | Heteroaryl amide analogues |
FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
ES2376092T3 (es) | 2008-04-22 | 2012-03-08 | Janssen Pharmaceutica, N.V. | Antagonistas de p2x7 sustituidos con quinolina o isoquinolina. |
WO2010060854A1 (en) | 2008-11-25 | 2010-06-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
RU2011147201A (ru) * | 2009-04-22 | 2013-05-27 | Янссен Фармацевтика Нв | Регероматические и ароматические пиперазинил ацетидинил амиды как моноцилглицероловые ингибиторы липазы |
ES2590987T3 (es) | 2009-04-29 | 2016-11-24 | Glaxo Group Limited | Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7 |
GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
ES2627688T3 (es) | 2010-04-02 | 2017-07-31 | Ogeda Sa | Novedosos compuestos antagonistas selectivos del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por los receptores de NK-3 |
US20110252717A1 (en) | 2010-04-16 | 2011-10-20 | Graf Fernandez Rodrigo | Foldable structures for a construction |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
IN2014MN02574A (es) | 2012-05-22 | 2015-07-24 | Genentech Inc | |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
EP3628662A1 (en) | 2012-10-15 | 2020-04-01 | Epizyme, Inc. | Substituted benzene compounds |
LT2909192T (lt) | 2012-10-16 | 2017-07-10 | Janssen Pharmaceutica Nv | Su metilenu sujungti rop-gama-t chinolinilo moduliatoriai |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
PE20151274A1 (es) | 2013-02-08 | 2015-09-12 | Celgene Avilomics Res Inc | Inhibidores de erk y sus usos |
NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
WO2014138368A1 (en) | 2013-03-06 | 2014-09-12 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
HUE053431T2 (hu) | 2013-03-14 | 2021-07-28 | Boehringer Ingelheim Int | Szubsztituált 2-aza-biciklo[2.2.1]heptán-3-karbonsav-(benzil-ciano-metil)-amidok, mint a katepszin-C inhibitorai |
US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | P2x7調節劑 |
JP6603649B2 (ja) | 2013-03-14 | 2019-11-06 | キュラデブ ファーマ プライベート リミテッド | キヌレニン経路の阻害剤 |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
AU2014241079C1 (en) | 2013-03-14 | 2017-07-06 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
SG11201506245QA (en) | 2013-03-14 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
ES2666155T3 (es) | 2013-03-14 | 2018-05-03 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
ES2721018T3 (es) | 2013-03-29 | 2019-07-26 | Ogeda S A | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 |
WO2015025026A1 (en) | 2013-08-22 | 2015-02-26 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
CA2960791C (en) | 2014-09-11 | 2023-03-14 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
AU2015315693B2 (en) | 2014-09-12 | 2020-01-16 | Janssen Pharmaceutica Nv | P2X7 modulating n-acyl-triazolopyrazines |
US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
KR20210069080A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
CN112272670B (zh) | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
AU2020358948A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
-
2019
- 2019-09-27 KR KR1020217012874A patent/KR20210069080A/ko unknown
- 2019-09-27 AU AU2019350624A patent/AU2019350624A1/en active Pending
- 2019-09-27 US US16/586,088 patent/US20200102303A1/en not_active Abandoned
- 2019-09-27 MX MX2021003737A patent/MX2021003737A/es unknown
- 2019-09-27 JP JP2021517202A patent/JP2022502424A/ja active Pending
- 2019-09-27 CA CA3111380A patent/CA3111380A1/en active Pending
- 2019-09-27 CR CR20210153A patent/CR20210153A/es unknown
- 2019-09-27 TW TW108135035A patent/TW202028198A/zh unknown
- 2019-09-27 EA EA202190886A patent/EA202190886A1/ru unknown
- 2019-09-27 BR BR112021005896-6A patent/BR112021005896A2/pt unknown
- 2019-09-27 SG SG11202102281VA patent/SG11202102281VA/en unknown
- 2019-09-27 PE PE2021000405A patent/PE20211773A1/es unknown
- 2019-09-27 WO PCT/IB2019/058240 patent/WO2020065613A1/en active Application Filing
- 2019-09-27 EP EP19780427.1A patent/EP3856178A1/en active Pending
- 2019-09-27 JO JOP/2021/0058A patent/JOP20210058A1/ar unknown
- 2019-09-27 MA MA053721A patent/MA53721A/fr unknown
- 2019-09-27 CN CN201980078969.1A patent/CN113164459A/zh active Pending
-
2020
- 2020-12-23 US US17/132,313 patent/US11820766B2/en active Active
-
2021
- 2021-03-22 PH PH12021550659A patent/PH12021550659A1/en unknown
- 2021-03-25 IL IL281812A patent/IL281812A/en unknown
- 2021-03-25 CL CL2021000757A patent/CL2021000757A1/es unknown
- 2021-03-26 EC ECSENADI202121381A patent/ECSP21021381A/es unknown
- 2021-03-26 NI NI202100023A patent/NI202100023A/es unknown
- 2021-03-29 CO CONC2021/0003944A patent/CO2021003944A2/es unknown
-
2022
- 2022-12-06 US US18/062,484 patent/US20230145249A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230145249A1 (en) | 2023-05-11 |
MA53721A (fr) | 2021-09-15 |
JP2022502424A (ja) | 2022-01-11 |
CO2021003944A2 (es) | 2021-04-19 |
AU2019350624A1 (en) | 2021-03-18 |
KR20210069080A (ko) | 2021-06-10 |
WO2020065613A1 (en) | 2020-04-02 |
JOP20210058A1 (ar) | 2021-03-24 |
US20220332713A1 (en) | 2022-10-20 |
PE20211773A1 (es) | 2021-09-08 |
PH12021550659A1 (en) | 2022-02-21 |
ECSP21021381A (es) | 2021-04-29 |
NI202100023A (es) | 2021-09-07 |
CR20210153A (es) | 2021-05-11 |
IL281812A (en) | 2021-05-31 |
CA3111380A1 (en) | 2020-04-02 |
EA202190886A1 (ru) | 2021-09-07 |
US11820766B2 (en) | 2023-11-21 |
EP3856178A1 (en) | 2021-08-04 |
US20200102303A1 (en) | 2020-04-02 |
SG11202102281VA (en) | 2021-04-29 |
CL2021000757A1 (es) | 2021-08-27 |
BR112021005896A2 (pt) | 2021-07-27 |
TW202028198A (zh) | 2020-08-01 |
CN113164459A (zh) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550659A1 (en) | Monoacylglycerol lipase modulators | |
MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
JOP20220180A1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
EA201100461A1 (ru) | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования | |
PH12015502001A1 (en) | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
MX2010010151A (es) | Moduladores de cinasa aurora y metodo de uso. | |
MX2022001181A (es) | Inhibidores de kif18a. | |
MX2021015511A (es) | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. | |
MX2021015508A (es) | Carbamatos de piridina y su uso como moduladores del receptor glun2b. | |
CO2021011919A2 (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes | |
JO3569B1 (ar) | مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها | |
MX2019007101A (es) | Derivados de oxazina como inhibidores de beta secretasa y metodos de uso. | |
MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
MX2019007102A (es) | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. | |
MX2019007103A (es) | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. | |
JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
EA201992127A1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
TN2020000161A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
MX2021009383A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
MX2022000841A (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. | |
MX2020012728A (es) | Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente. |